SCYNEXIS (SCYX) Competitors $1.05 -0.06 (-5.77%) (As of 02:52 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SCYX vs. NKTX, CKPT, SCPH, ZURA, CDTX, VTYX, TCRX, MCRB, NBTX, and FTLFShould you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Nkarta (NKTX), Checkpoint Therapeutics (CKPT), scPharmaceuticals (SCPH), Zura Bio (ZURA), Cidara Therapeutics (CDTX), Ventyx Biosciences (VTYX), TScan Therapeutics (TCRX), Seres Therapeutics (MCRB), Nanobiotix (NBTX), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. SCYNEXIS vs. Nkarta Checkpoint Therapeutics scPharmaceuticals Zura Bio Cidara Therapeutics Ventyx Biosciences TScan Therapeutics Seres Therapeutics Nanobiotix FitLife Brands SCYNEXIS (NASDAQ:SCYX) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, community ranking, dividends, risk, institutional ownership, media sentiment and analyst recommendations. Which has stronger earnings & valuation, SCYX or NKTX? SCYNEXIS has higher revenue and earnings than Nkarta. SCYNEXIS is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSCYNEXIS$8.57M4.92$67.04M-$0.74-1.50NkartaN/AN/A-$117.50M-$1.88-1.21 Is SCYX or NKTX more profitable? Nkarta has a net margin of 0.00% compared to SCYNEXIS's net margin of -425.41%. Nkarta's return on equity of -27.13% beat SCYNEXIS's return on equity.Company Net Margins Return on Equity Return on Assets SCYNEXIS-425.41% -66.21% -38.84% Nkarta N/A -27.13%-21.67% Does the MarketBeat Community prefer SCYX or NKTX? SCYNEXIS received 445 more outperform votes than Nkarta when rated by MarketBeat users. However, 76.92% of users gave Nkarta an outperform vote while only 70.04% of users gave SCYNEXIS an outperform vote. CompanyUnderperformOutperformSCYNEXISOutperform Votes50570.04% Underperform Votes21629.96% NkartaOutperform Votes6076.92% Underperform Votes1823.08% Do analysts prefer SCYX or NKTX? Nkarta has a consensus price target of $15.00, suggesting a potential upside of 560.79%. Given Nkarta's stronger consensus rating and higher possible upside, analysts plainly believe Nkarta is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Nkarta 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Do institutionals & insiders hold more shares of SCYX or NKTX? 54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 2.9% of SCYNEXIS shares are held by insiders. Comparatively, 8.7% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, SCYX or NKTX? SCYNEXIS has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Does the media refer more to SCYX or NKTX? In the previous week, SCYNEXIS's average media sentiment score of 0.00 beat Nkarta's score of -0.41 indicating that SCYNEXIS is being referred to more favorably in the media. Company Overall Sentiment SCYNEXIS Neutral Nkarta Neutral SummaryNkarta beats SCYNEXIS on 11 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get SCYNEXIS News Delivered to You Automatically Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCYX vs. The Competition Export to ExcelMetricSCYNEXISPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.12M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-1.5010.75135.1817.53Price / Sales4.92287.861,235.42140.39Price / Cash0.6056.6540.6537.95Price / Book0.575.394.884.92Net Income$67.04M$152.04M$118.97M$225.78M7 Day Performance-5.93%-4.32%16.19%-1.58%1 Month Performance-5.13%2.80%16.02%6.67%1 Year Performance-34.71%17.30%34.95%22.48% SCYNEXIS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCYXSCYNEXIS0.9022 of 5 stars$1.05-5.8%N/A-30.6%$39.69M$8.57M-1.4160News CoverageNKTXNkarta3.166 of 5 stars$2.34flat$15.00+541.0%-29.1%$165.13MN/A-1.24140Gap UpCKPTCheckpoint Therapeutics3.8529 of 5 stars$3.37-8.2%$10.33+206.6%+11.9%$164.56M$100,000.00-1.8310Analyst ForecastOptions VolumeNews CoverageGap UpHigh Trading VolumeSCPHscPharmaceuticals3.6525 of 5 stars$3.28+2.8%$15.00+357.3%-43.2%$164.13M$13.59M-1.6830ZURAZura Bio3.3088 of 5 stars$2.50+9.6%$15.80+532.0%-45.2%$163.23MN/A0.003CDTXCidara Therapeutics3.7721 of 5 stars$23.00+0.5%$32.20+40.0%+59.4%$162.15M$63.90M-0.9090Short Interest ↑VTYXVentyx Biosciences3.2222 of 5 stars$2.28flat$10.00+338.6%+5.3%$161.22MN/A-0.9773News CoverageTCRXTScan Therapeutics2.8129 of 5 stars$3.00+5.3%$11.25+275.0%-40.0%$160.11M$21.05M-2.69100MCRBSeres Therapeutics3.5788 of 5 stars$0.92+5.0%$5.08+451.0%-11.3%$157.51M$126.33M-4.04233News CoverageGap UpNBTXNanobiotix1.6801 of 5 stars$3.34+0.3%$12.00+259.3%-43.3%$157.42M$36.22M0.00100News CoverageGap UpFTLFFitLife Brands3.3535 of 5 stars$33.50-1.5%$40.00+19.4%+51.2%$154.03M$62.76M20.1220 Related Companies and Tools Related Companies NKTX Alternatives CKPT Alternatives SCPH Alternatives ZURA Alternatives CDTX Alternatives VTYX Alternatives TCRX Alternatives MCRB Alternatives NBTX Alternatives FTLF Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SCYX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredFREE Book That Could Make You a Millionaire[FREE BOOK] Can You Make a Fortune in Crypto with $50? Get started now before the market takes off! Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
